NCT04915950View on ClinicalTrials.gov

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
DRUG

Temanogrel

Participants will receive a single oral dose of temanogrel during the treatment visit.

DRUG

Placebo

Participants will receive a single oral dose of temanogrel matching placebo during the treatment visit.

Trial Locations (6)

15213

UPMC Arthritis and Auotimmune Clinic, Pittsburgh

21224

Johns Hopkins Asthma and Allergy Center, Baltimore

06519

Yale University, New Haven

DD1 9SY

Ninewells Hospital & Medical School, Dundee

BAI 3NG

Royal United Hospitals Bath, Bath

M6 8HD

Salford Royal Hospital, Salford

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arena is a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Pfizer

INDUSTRY

NCT04915950 - A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis | Biotech Hunter | Biotech Hunter